Monday, July 15, 2024

CATEGORY

Johnson & Johnson

Multiple Myeloma Treatment: Carvykti Shows Significant Improvement in Relapsed or Lenalidomide-Refractory Patients After One Prior Therapy

Multiple myeloma patients with relapsed or lenalidomide-refractory disease, after receiving one prior line of therapy, showed statistically significant and clinically meaningful improvement in overall...

Pulmonary Tuberculosis Treatment Gains Full FDA and EC Approval for Johnson & Johnson’s SIRTURO®

Johnson & Johnson has received traditional approval from the U.S. Food and Dug Administration (FDA) and full approval from the European Commission (EC) for...

Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again

For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...

Nipocalimab’s Phase 3 Trial Shows Promising Myasthenia Gravis Results

Nipocalimab has shown significant promise in the treatment of generalized myasthenia gravis (gMG) in a recent Phase 3 trial. The study, conducted by Johnson...

Erdafitinib Gains Positive CHMP Opinion for Urothelial Carcinoma

Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Multiple Myeloma Treatment with TECVAYLI® Shows Promising Long-Term Efficacy

Johnson & Johnson announced long-term data from the MajesTEC-1 study showing TECVAYLI® (teclistamab-cqyv) offers deep and durable responses in relapsed or refractory multiple myeloma...

Multiple Myeloma Outcomes Significantly Improved by DARZALEX® Regimens, Announces Johnson & Johnson

Johnson & Johnson announced that DARZALEX® (daratumumab)-based regimens significantly improve outcomes in both transplant-eligible and ineligible patients newly diagnosed with multiple myeloma. In the...

Multiple Myeloma Advances with Durable TALVEY® Responses, Reports Johnson & Johnson

Johnson & Johnson recently announced long-term data from the Phase 1/2 MonumenTAL-1 study, demonstrating durable responses in patients with relapsed or refractory multiple myeloma...

Lung Cancer Treatment Advances as Johnson & Johnson Submits BLA for SC Amivantamab to FDA

Johnson & Johnson has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed SC combination of...

Crohn’s Disease Study Shows Positive Results for Johnson & Johnson’s TREMFYA® in Phase 3 Trial

Johnson & Johnson has announced positive topline results from the pivotal Phase 3 GRAVITI study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults...

Latest news